You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The program will support Johns Hopkins' research into saliva testing and diagnostics and will help GBS form its commercialization strategy for two saliva-based tests.
For the first time, WHO's essential diagnostics list includes tests that it recommends should also not be supplied because they are unreliable, among other reasons.
Though its point-of-care revenues fell, the firm's clinical laboratory sales for the third quarter rose 44 percent over the prior-year quarter
The ELISA-based test, which has CE marking, uses protein signatures in blood to detect the onset of kidney disease in type 2 diabetics.
The companies are currently working together to commercialize their respective products including genetic tests for type 2 diabetes and gestational diabetes risk.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
The company said it is developing a rapid COVID-19 antibody test that will provide results in 12 minutes using a finger prick of blood.
KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.
The point-of-care system is designed to measure glycated hemoglobin levels in whole blood for use in the monitoring and management of diabetes.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.